• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Organogenesis Holdings Inc. (Amendment)

    12/30/21 4:21:59 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ORGO alert in real time by email
    SC 13D/A 1 d254756dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 6)*

     

     

    Organogenesis Holdings Inc.

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    68621F102

    (CUSIP Number)

    Lori Freedman

    Vice President and General Counsel

    Organogenesis Holdings Inc.

    85 Dan Road

    Canton, MA 02021

    Tel: (781) 575-0775

    With a copy to:

    William R. Kolb

    Stacie S. Aarestad

    Foley Hoag LLP

    155 Seaport Boulevard

    Boston, MA 02210

    Tel: (617) 832-1000

    Fax: (617) 832-7000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    December 28, 2021

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.  ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 68621F102    13D    Page 2 of 20 Pages

     

      1.    

      Names of Reporting Persons.

     

      Alan A. Ades

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      OO, PF

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.     

      Sole Voting Power

     

      15,244,272 Shares

         8.   

      Shared Voting Power

     

      11,131,474 Shares

         9.   

      Sole Dispositive Power

     

      15,244,272 Shares

       10.   

      Shared Dispositive Power

     

      11,131,474 Shares

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      26,375,746 Shares

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row (11)

     

      20.5%

    14.  

      Type of Reporting Person (See Instructions)

     

      IN, OO

     

     


    CUSIP No. 68621F102    13D    Page 3 of 20 Pages

     

      1.    

      Names of Reporting Persons

     

      Albert Erani

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      OO

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.     

      Sole Voting Power

     

      8,044,917 Shares

         8.   

      Shared Voting Power

     

      11,131,474 Shares

         9.   

      Sole Dispositive Power

     

      8,044,917 Shares

       10.   

      Shared Dispositive Power

     

      11,131,474 Shares

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      19,176,391 Shares

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row (11)

     

      14.9%

    14.  

      Type of Reporting Person (See Instructions)

     

      IN, OO


    CUSIP No. 68621F102    13D    Page 4 of 20 Pages

     

      1.    

      Names of Reporting Persons.

     

      Glenn H. Nussdorf

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      OO

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.     

      Sole Voting Power

     

      13,544,983 Shares

         8.   

      Shared Voting Power

     

      1,418,680 Shares

         9.   

      Sole Dispositive Power

     

      13,544,983 Shares

       10.   

      Shared Dispositive Power

     

      1,418,680 Shares

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      14,963,663 Shares

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row (11)

     

      11.6%

    14.  

      Type of Reporting Person (See Instructions)

     

      IN, OO


    CUSIP No. 68621F102    13D    Page 5 of 20 Pages

     

      1.    

      Names of Reporting Persons.

     

      Dennis Erani

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      OO, PF

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.     

      Sole Voting Power

     

      1,314,517 Shares

         8.   

      Shared Voting Power

     

      8,729,184 Shares

         9.   

      Sole Dispositive Power

     

      1,314,517 Shares

       10.   

      Shared Dispositive Power

     

      8,729,184 Shares

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      10,043,701 Shares

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row (11)

     

      7.8%

    14.  

      Type of Reporting Person (See Instructions)

     

      IN, OO


    CUSIP No. 68621F102    13D    Page 6 of 20 Pages

     

      1.    

      Names of Reporting Persons.

     

      Starr Wisdom

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      OO

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.     

      Sole Voting Power

     

      20,000 Shares

         8.   

      Shared Voting Power

     

      0

         9.   

      Sole Dispositive Power

     

      20,000 Shares

       10.   

      Shared Dispositive Power

     

      0

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      20,000 Shares

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row (11)

     

      0.0%

    14.  

      Type of Reporting Person (See Instructions)

     

      IN

     


    CUSIP No. 68621F102    13D    Page 7 of 20 Pages

     

      1.    

      Names of Reporting Persons.

     

      Organo PFG LLC

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      OO

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.     

      Sole Voting Power

     

      8,279,490 Shares

         8.   

      Shared Voting Power

     

      0

         9.   

      Sole Dispositive Power

     

      8,279,490 Shares

       10.   

      Shared Dispositive Power

     

      0

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      8,279,490 Shares

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row (11)

     

      6.4%

    14.  

      Type of Reporting Person (See Instructions)

     

      OO


    CUSIP No. 68621F102    13D    Page 8 of 20 Pages

     

      1.    

      Names of Reporting Persons.

     

      Organo Investors LLC

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      OO

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.     

      Sole Voting Power

     

      2,851,984 Shares

         8.   

      Shared Voting Power

     

      0

         9.   

      Sole Dispositive Power

     

      2,851,984 Shares

       10.   

      Shared Dispositive Power

     

      0

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      2,851,984 Shares

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row (11)

     

      2.2%

    14.  

      Type of Reporting Person (See Instructions)

     

      OO


    CUSIP No. 68621F102    13D    Page 9 of 20 Pages

     

      1.    

      Names of Reporting Persons.

     

      Alan Ades 2014 GRAT

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      OO

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.     

      Sole Voting Power

     

      6,837,774 Shares

         8.   

      Shared Voting Power

     

      0

         9.   

      Sole Dispositive Power

     

      6,837,774 Shares

       10.   

      Shared Dispositive Power

     

      0

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      6,837,774 Shares

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row (11)

     

      5.3%

    14.  

      Type of Reporting Person (See Instructions)

     

      OO


    CUSIP No. 68621F102    13D    Page 10 of 20 Pages

     

      1.    

      Names of Reporting Persons.

     

      Albert Erani Family Trust dated 12/29/2012

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      OO

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.     

      Sole Voting Power

     

      0 Shares

         8.   

      Shared Voting Power

     

      0

         9.   

      Sole Dispositive Power

     

      0 Shares

       10.   

      Shared Dispositive Power

     

      0

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      0 Shares

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row (11)

     

      0.0%

    14.  

      Type of Reporting Person (See Instructions)

     

      OO


    CUSIP No. 68621F102    13D    Page 11 of 20 Pages

     

      1.    

      Names of Reporting Persons.

     

      Dennis Erani 2012 Issue Trust dated 12/20/12

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      OO

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.     

      Sole Voting Power

     

      8,382,031 Shares

         8.   

      Shared Voting Power

     

      0

         9.   

      Sole Dispositive Power

     

      8,382,031 Shares

       10.   

      Shared Dispositive Power

     

      0

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      8,382,031 Shares

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row (11)

     

      6.5%

    14.  

      Type of Reporting Person (See Instructions)

     

      OO


    CUSIP No. 68621F102    13D    Page 12 of 20 Pages

     

      1.    

      Names of Reporting Persons.

     

      GN 2016 Family Trust u/a/d August 12, 2016

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      OO

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.     

      Sole Voting Power

     

      1,418,680 Shares

         8.   

      Shared Voting Power

     

      0

         9.   

      Sole Dispositive Power

     

      1,418,680 Shares

       10.   

      Shared Dispositive Power

     

      0

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      1,418,680 Shares

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row (11)

     

      1.1%

    14.  

      Type of Reporting Person (See Instructions)

     

      OO


    CUSIP No. 68621F102    13D    Page 13 of 20 Pages

     

      1.    

      Names of Reporting Persons.

     

      GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      OO

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.     

      Sole Voting Power

     

      10,761,320 Shares

         8.   

      Shared Voting Power

     

      0

         9.   

      Sole Dispositive Power

     

      10,761,320 Shares

       10.   

      Shared Dispositive Power

     

      0

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      10,761,320 Shares

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row (11)

     

      8.4%

    14.  

      Type of Reporting Person (See Instructions)

     

      OO


    CUSIP No. 68621F102    13D    Page 14 of 20 Pages

     

      1.    

      Names of Reporting Persons.

     

      RED Holdings, LLC

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☒        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Source of Funds (See Instructions)

     

      OO

      5.  

      Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)

     

      ☐

      6.  

      Citizenship or Place of Organization

     

      United States

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

     

         7.     

      Sole Voting Power

     

      7,392,328 Shares

         8.   

      Shared Voting Power

     

      0

         9.   

      Sole Dispositive Power

     

      7,392,328 Shares

       10.   

      Shared Dispositive Power

     

      0

    11.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      7,392,328 Shares

    12.  

      Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)

     

      ☐

    13.  

      Percent of Class Represented by Amount in Row (11)

     

      5.7%

    14.  

      Type of Reporting Person (See Instructions)

     

      OO


    CUSIP No. 68621F102       Page 15 of 20 Pages

     

    This Amendment No. 6 (this “Amendment No. 6”) amends and supplements the beneficial ownership statement on Schedule 13D originally filed on December 20, 2018 on behalf of Alan A. Ades, Albert Erani, Glenn H. Nussdorf, Dennis Erani, Starr Wisdom, Organo PFG LLC, Organo Investors LLC, Dennis Erani 2012 Issue Trust dated 12/20/12, Alan Ades 2014 GRAT, Albert Erani Family Trust dated 12/29/2012, GN 2016 Family Trust u/a/d August 12, 2016 and GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 (collectively, the “Group”), as amended by Amendment No. 1 to the statement on Schedule 13D filed on November 27, 2019, Amendment No. 2 to the statement on Schedule 13D filed on November 19, 2020, Amendment No. 3 to the statement on Schedule 13D filed on May 11, 2021, Amendment No. 4 to the statement on Schedule 13D filed on June 1, 2021 and Amendment No. 5 to the statement on Schedule 13D filed on December 17, 2021 (such Schedule 13D and amendments, the “Original Statement”). The Original Statement, as amended by this Amendment No. 6 (the “Statement”), relates to the shares of Class A common stock, par value $0.0001 per share (the “Shares”), of Organogenesis Holdings Inc., a Delaware corporation (the “Issuer”).

    Capitalized terms used herein but not otherwise defined shall have the meanings ascribed to them in the Original Statement. This Amendment No. 6 amends the Original Statement as specifically set forth herein. Except as set forth in this Amendment No. 6, all previous Items in the Original Statement remain unchanged.

    Item 2. Identity and Background.

    Item 2 of the Original Statement is hereby amended and restated as follows:

    “ (a) The names of the reporting persons are Alan A. Ades, Albert Erani, Glenn H. Nussdorf, Dennis Erani, Starr Wisdom, Organo PFG LLC (“Organo PFG”), Organo Investors LLC (“Organo Investors”), Dennis Erani 2012 Issue Trust dated 12/20/12 (the “D. Erani Trust”), Alan Ades as Trustee of the Alan Ades 2014 GRAT (the “A. Ades GRAT”), Albert Erani Family Trust dated 12/29/2012 (the “A. Erani Trust”), GN 2016 Family Trust u/a/d August 12, 2016 (the “GN Trust”), GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 (the “GN GRAT”) and RED Holdings, LLC (“RED Holdings”). The reporting persons are collectively referred to herein as the “Reporting Persons” or the “Controlling Entities”. The D. Erani Trust, the A. Ades GRAT, the A. Erani Trust, the GN Trust and the GN GRAT are collectively referred to as the “Trusts”.

    (b) The business address of each of Alan Ades, Organo PFG, Organo Investors, the A. Ades GRAT, Albert Erani, the A. Erani Trust and RED Holdings, c/o Rugby Realty Co., is 300 Lighting Way, Secaucus, NJ 07094. The address of each of Dennis Erani and the D. Erani Trust is 6000 Island Boulevard, Apt. 2502, Aventura, FL 33160. The business address of Mr. Nussdorf, the GN Trust and the GN GRAT is 35 Sawgrass Drive, Bellport, NY 11713. The address of Starr Wisdom is 44 Wilson Street, Hartsdale, NY 10530.

    (c) Each of Albert Erani and Dennis Erani is retired. The present principal occupation or employment of Alan Ades is principal of Rugby Realty Co., Inc., an entity that owns real estate partnerships and is located at 300 Lighting Way, Secaucus, NJ 07094. The present principal occupation or employment of Mr. Nussdorf is President and Chief Executive Officer of Quality King Distributors, Inc., a distributor of health and beauty care products and prescription drugs located at 35 Sawgrass Drive, Bellport, NY 11713. Ms. Wisdom is not currently employed.


    CUSIP No. 68621F102       Page 16 of 20 Pages

     

    The principal business of each of Organo PFG, Organo Investors and RED Holdings is holding, managing, investing and distributing shares of the Issuer and the proceeds therefrom. The principal business of each of the Trusts is holding, managing, investing and distributing the trust property and the proceeds therefrom. The Trusts were formed for estate planning purposes.

    (d) None of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

    (e) None of the Reporting Persons was, during the last five years, a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and, as a result of such proceeding, was or is subject to a judgment, decree or final order (1) enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or (2) finding any violation with respect to such laws.

    (f) Each of Alan Ades, Albert Erani, Mr. Nussdorf, Dennis Erani and Ms. Wisdom is a citizen of the United States. Each of the Trusts, Organo PFG, Organo Investors and RED Holdings, LLC was formed and operates in the United States.

    Item 5. Interest in Securities of the Issuer.

    Paragraph (a) of Item 5 of the Original Statement is hereby amended and restated as follows:

    “The percentages of beneficial ownership reported in this Item 5, and on each Reporting Person’s cover page to this Statement, are based on a total of 128,641,628 Shares as reported in the quarterly report on Form 10-Q filed by the Issuer on November 9, 2021. All of the Share numbers reported below, and on each Reporting Person’s cover page to this Statement, are as of December 28, 2021. The cover page to this Statement for each Reporting Person is incorporated by reference in its entirety into this Item 5.

    (a) Alan A. Ades is the beneficial owner of a total of 26,375,746 Shares, representing approximately 20.5% of the outstanding Shares and consisting of (i) 8,406,498 Shares held by Alan Ades, (ii) 6,837,774 Shares held by the A. Ades GRAT, (iii) 8,279,490 Shares held by Organo PFG and (iv) 2,851,984 Shares held by Organo Investors.

    Albert Erani is the beneficial owner of a total of 19,176,391 Shares, representing approximately 14.9% of the outstanding Shares and consisting of (i) 652,589 Shares held by Albert Erani, (ii) 7,392,328 Shares held by RED Holdings, (iii) 8,279,490 Shares held by Organo PFG and (iv) 2,851,984 Shares held by Organo Investors.

    Dennis Erani is the beneficial owner of a total of 10,043,701 Shares, representing approximately 7.8% of the outstanding Shares and consisting of (i) 1,314,517 Shares held by Dennis Erani, (ii) 8,382,031 Shares held by the D. Erani Trust and (iii) 347,153 Shares held by the Purchasing Trust. Susan Erani, who is Dennis Erani’s spouse, and Mr. Nussdorf are co-trustees of the Purchasing Trust.

    Glenn H. Nussdorf is the beneficial owner of a total of 14,963,663 Shares, representing approximately 11.6% of the outstanding Shares and consisting of (i) 2,783,663 Shares held by Mr. Nussdorf, (ii) 1,418,680 Shares held by the GN Trust and (iii) 10,761,320 Shares held by the GN GRAT.


    CUSIP No. 68621F102       Page 17 of 20 Pages

     

    Starr Wisdom is the beneficial owner of a total of 20,000 Shares, representing approximately 0.0% of the outstanding Shares. Ms. Wisdom holds all such Shares directly.

    Organo PFG is the beneficial owner of a total of 8,279,490 Shares, representing approximately 6.4% of the outstanding Shares. Organo PFG holds all such Shares directly. Alan Ades and Albert Erani are the managing members of Organo PFG.

    Organo Investors is the beneficial owner of a total of 2,851,984 Shares, representing approximately 2.2% of the outstanding Shares. Organo Investors holds all such Shares directly. Alan Ades and Albert Erani are the managers of Organo Investors.

    The A. Ades GRAT is the beneficial owner of a total of 6,837,774 Shares, representing approximately 5.3% of the outstanding Shares. The A. Ades GRAT holds all such Shares directly. Alan Ades is trustee of the A. Ades GRAT.

    The A. Erani Trust does not beneficially own any Shares. Starr Wisdom, John Wisdom and Jeffrey Baddish are co-trustees of the A. Erani Trust.

    The D. Erani Trust is the beneficial owner of a total of 8,382,031 Shares, representing approximately 6.5% of the outstanding Shares. The D. Erani Trust holds all such Shares directly. Mr. Nussdorf, Susan Erani, who is Dennis Erani’s spouse, and David Peretz are co-trustees of the D. Erani Trust.

    The GN Trust is the beneficial owner of a total of 1,418,680 Shares, representing approximately 1.1% of the outstanding Shares. The GN Trust holds all such Shares directly. Michael Katz is the trustee of the GN Trust.

    The GN GRAT is the beneficial owner of a total of 10,761,320 Shares, representing approximately 8.4% of the outstanding Shares. The GN GRAT holds all such Shares directly. Mr. Nussdorf is trustee of the GN GRAT.

    RED Holdings is the beneficial owner of 7,392,328 Shares, representing approximately 5.7% of the outstanding Shares. RED Holdings holds all such Shares directly. Albert Erani is the sole manager of RED Holdings and the 2021 RED Trust is the sole member of RED Holdings.

    By virtue of the relationships described in this Statement, the Reporting Persons may be deemed to constitute a “group” within the meaning of Rule 13d-5 under the Act. The filing of this Statement shall not be construed as an admission that a Reporting Person beneficially owns those shares held by another member of such group for purposes of Section 13(d) of the Act or for any other purpose. In addition, each Reporting Person expressly disclaims beneficial ownership of any securities reported herein except to the extent such Reporting Person actually exercises voting or dispositive power with respect to such securities.”

    Paragraph (c) of Item 5 of the Original Statement is hereby amended and restated as follows:

    “ (c) On December 28, 2021, the Albert Erani 2014 GRAT transferred 4,661,129 Shares to the A. Erani Trust (the “A. Erani GRAT Transfer”) and, immediately thereafter, the A. Erani Trust transferred 7,392,328 Shares to RED Holdings (the “A. Erani Trust Transfer”), in each case, as a gift for no consideration for estate planning purposes.


    CUSIP No. 68621F102       Page 18 of 20 Pages

     

    On December 15, 2021, the Dennis Erani 2014 GRAT transferred 5,417,900 Shares to the D. Erani Trust as a gift for no consideration for estate planning purposes (the “Dennis Erani 2014 GRAT Transfer”).

    On November 18, 2021, Glenn Nussdorf purchased 25,000 Shares on the open market at a weighted-average price of $9.93 per Share. Except for such purchase, the Dennis Erani 2014 GRAT Transfer, the A. Erani Trust Transfer and the A. Erani GRAT Transfer, none of the members of the Group has effected any transactions in Shares during the past 60 days.”

    Item 7. Material to be Filed as Exhibits.

    Item 7 of the Original Statement is hereby supplemented as follows:

     

    Exhibit No.

      

    Exhibit

    99.15    RED Holdings Joint Filing Agreement, dated as of December 30, 2021, filed herewith.
    99.16    Power of Attorney, relating to RED Holdings (incorporated by reference to Exhibit 24.1 of the Form 3 filed by RED Holdings on December 27, 2021).
    99.17    Joinder Agreement of RED Holdings, dated as of December 15, 2021, filed herewith.

    [signature page follows]


    CUSIP No. 68621F102       Page 19 of 20 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.

    December 30, 2021

     

    ALAN A. ADES
    By: /s/ Stacie S. Aarestad, Attorney-in-fact                
    Stacie S. Aarestad, Attorney-in-fact
    ALBERT ERANI
    By: /s/ Stacie S. Aarestad, Attorney-in-fact                
    Stacie S. Aarestad, Attorney-in-fact
    DENNIS ERANI
    By: /s/ Stacie S. Aarestad, Attorney-in-fact                
    Stacie S. Aarestad, Attorney-in-fact
    GLENN H. NUSSDORF
    By: /s/ Stacie S. Aarestad, Attorney-in-fact                
    Stacie S. Aarestad, Attorney-in-fact
    STARR WISDOM
    By: /s/ Stacie S. Aarestad, Attorney-in-fact                
    Stacie S. Aarestad, Attorney-in-fact
    ORGANO PFG LLC
    By: /s/ Stacie S. Aarestad, Attorney-in-fact                
    Stacie S. Aarestad, Attorney-in-fact


    CUSIP No. 68621F102       Page 20 of 20 Pages

     

    ORGANO INVESTORS LLC
    By:  

    /s/ Stacie S. Aarestad, Attorney-in-fact

    Stacie S. Aarestad, Attorney-in-fact
    ALAN ADES 2014 GRAT
    By:  

    /s/ Stacie S. Aarestad, Attorney-in-fact

    Stacie S. Aarestad, Attorney-in-fact
    ALBERT ERANI FAMILY TRUST DATED
    12/29/2012
    By:  

    /s/ Stacie S. Aarestad, Attorney-in-fact

    Stacie S. Aarestad, Attorney-in-fact
    DENNIS ERANI 2012 ISSUE TRUST DATED
    12/20/12
    By:  

    /s/ Stacie S. Aarestad, Attorney-in-fact

    Stacie S. Aarestad, Attorney-in-fact
    GN 2016 FAMILY TRUST U/A/D AUGUST 12, 2016
    By:  

    /s/ Stacie S. Aarestad, Attorney-in-fact

    Stacie S. Aarestad, Attorney-in-fact
    GN 2016 ORGANO 10-YEAR GRAT U/A/D SEPTEMBER 30, 2016
    By:  

    /s/ Stacie S. Aarestad, Attorney-in-fact

    Stacie S. Aarestad, Attorney-in-fact

    RED HOLDINGS, LLC

    By:  

    /s/ Stacie S. Aarestad, Attorney-in-fact

    Stacie S. Aarestad, Attorney-in-fact


    Exhibit 99.15

    JOINT FILING AGREEMENT

    The undersigned hereby agrees that it is filing this statement jointly pursuant to Rule 13d-1(k)(1). The undersigned is responsible for the timely filing of any additional amendments to the Schedule 13D initially filed on December 20, 2018 (the “Schedule 13D”), and for the completeness and accuracy of the information concerning the undersigned contained therein or in any amendments thereto; but the undersigned is not responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless the undersigned knows or has reason to believe that such information is inaccurate.

    In accordance with Rule 13d-1(k)(1) promulgated under the Securities and Exchange Act of 1934, as amended, the undersigned hereby agrees to the joint filing with the other reporting persons who have signed the statement on Schedule 13D (and any amendments thereto) with respect to the Common Stock, par value $0.0001, beneficially owned by each of them, of Organogenesis Holdings Inc., a corporation incorporated under the laws of the State of Delaware. This Joint Filing Agreement shall be included as an exhibit to such Schedule 13D, as amended.

     

    Dated: December 30, 2021     By:  

    *

          RED Holdings, LLC

     

    *

    The undersigned, by signing her name hereto, executes this Joint Filing Agreement pursuant to the Powers of Attorney executed on behalf of the entity listed above and filed herewith.

     

    By:  

    /s/ Stacie S. Aarestad, Attorney-in-fact

      Stacie S. Aarestad, Attorney-in-fact


    Exhibit 99.17

    JOINDER AGREEMENT

    The undersigned is executing and delivering this Joinder Agreement pursuant to the Controlling Stockholders’ Agreement (the “Agreement”), dated as of December 10, 2018 and as it may be amended from time to time in accordance with its terms, by and among Organogenesis Holdings Inc. and the Stockholders party thereto.

    Capitalized terms used but not defined herein shall have the meaning ascribed to such terms in the Agreement.

    By executing and delivering this Joinder Agreement to the Agreement, the undersigned hereby adopts and approves the Agreement and agrees, effective commencing on the date hereof and as a condition to and immediately prior the undersigned’s becoming the transferee of shares of Common Stock, to be bound by and to comply with the provisions of the Agreement applicable to the Stockholders party thereto, in the same manner as if the undersigned were an original signatory to the Agreement.

    Accordingly, the undersigned has executed and delivered this Joinder as of the 15th day of December, 2021.

     

    RED HOLDINGS, LLC
    By:  

    /s/ Albert Erani

      Name: Albert Erani
      Title: Manager
    Address:   RED Holdings, LLC
      c/o The Corporation Service Company
      251 Little Falls Drive
      Wilmington, New Castle County, DE 19808
    Attention: Albert Erani
    Facsimile:  

     

    Get the next $ORGO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ORGO

    DatePrice TargetRatingAnalyst
    6/28/2024$5.00Buy
    Lake Street
    2/7/2024$5.00Overweight
    Cantor Fitzgerald
    6/15/2023$5.00Equal-Weight
    Morgan Stanley
    5/24/2023$10.00Neutral → Buy
    BTIG Research
    11/10/2022Buy → Neutral
    BTIG Research
    8/10/2022Outperform → Perform
    Oppenheimer
    11/10/2021$26.00 → $20.00Outperform
    SVB Leerink
    8/10/2021$24.00 → $25.00Outperform
    Credit Suisse
    More analyst ratings

    $ORGO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Avista Healthcare Partners Announces Promotions

    NEW YORK, Jan. 5, 2026 /PRNewswire/ -- Avista Healthcare Partners ("Avista"), a leading private equity firm focused exclusively on healthcare, today announced three key promotions within its investment team, reflecting the firm's continued growth and commitment to developing top talent. Ryan Moran has been promoted to Partner;Garrett Lustig has been promoted to Partner; andElaine Tang has been promoted to Principal.David Burgstahler, Managing Partner and Chief Executive Officer of Avista, commented:"We are thrilled to recognize Ryan, Garrett, and Elaine for their outstanding contributions to Avista's success as well as their partnerships with our portfolio company management teams and Board

    1/5/26 8:00:00 AM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organogenesis Announces Initiation of Biologics License Application for ReNu®

    CANTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the initiation of a rolling submission of a Biologics License Application (BLA) to the Food and Drug Administration (FDA) for ReNu,® a cryopreserved, amniotic suspension allograft developed for the management of symptomatic knee arthritis. Organogenesis plans to complete the BLA submission with the final modules submitted in the first half of 2026. "This is another significant achievement for

    12/23/25 4:05:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain

    Clinical Development Program Appropriate for Rolling BLA  Submission Expected by the End of 2025 CANTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced the successful completion of a planned Type-B meeting with the Food and Drug Administration (FDA) resulting in confirmation to initiate a rolling Biologics Licenses Application (BLA) for ReNu planned before the end of December. "We are excited about the outcome of our FDA meeting and reaching thi

    12/15/25 4:25:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Nussdorf Glenn H sold $1,027,060 worth of shares (200,000 units at $5.14), decreasing direct ownership by 7% to 2,565,591 units (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    12/18/25 4:19:19 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Nussdorf Glenn H sold $1,592,120 worth of shares (300,000 units at $5.31), decreasing direct ownership by 10% to 2,765,591 units (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    11/26/25 6:24:24 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Nussdorf Glenn H bought $1,096,039 worth of shares (358,495 units at $3.06) and sold $80,803 worth of shares (22,776 units at $3.55) (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    11/3/25 5:25:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Nussdorf Glenn H bought $1,096,039 worth of shares (358,495 units at $3.06) and sold $80,803 worth of shares (22,776 units at $3.55) (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    11/3/25 5:25:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Admin. and Legal Officer Freedman Lori bought $725,290 worth of shares (252,264 units at $2.88), increasing direct ownership by 42% to 846,459 units (SEC Form 4)

    4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

    6/6/25 5:44:18 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Organogenesis with a new price target

    Lake Street initiated coverage of Organogenesis with a rating of Buy and set a new price target of $5.00

    6/28/24 8:20:16 AM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Organogenesis with a new price target

    Cantor Fitzgerald initiated coverage of Organogenesis with a rating of Overweight and set a new price target of $5.00

    2/7/24 6:56:39 AM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on Organogenesis with a new price target

    Morgan Stanley initiated coverage of Organogenesis with a rating of Equal-Weight and set a new price target of $5.00

    6/15/23 7:30:00 AM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGO
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Organogenesis Holdings Inc.

    SCHEDULE 13G/A - Organogenesis Holdings Inc. (0001661181) (Subject)

    2/12/26 5:01:32 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Organogenesis Holdings Inc.

    8-K - Organogenesis Holdings Inc. (0001661181) (Filer)

    12/29/25 4:31:02 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Organogenesis Holdings Inc.

    144 - Organogenesis Holdings Inc. (0001661181) (Subject)

    12/16/25 4:32:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Organogenesis Holdings Inc.

    SC 13D - Organogenesis Holdings Inc. (0001661181) (Subject)

    11/19/24 4:05:57 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Organogenesis Holdings Inc.

    SC 13D/A - Organogenesis Holdings Inc. (0001661181) (Subject)

    11/14/24 8:09:56 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Organogenesis Holdings Inc.

    SC 13G/A - Organogenesis Holdings Inc. (0001661181) (Subject)

    11/14/24 3:35:42 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGO
    Leadership Updates

    Live Leadership Updates

    View All

    Organogenesis Expands Manufacturing Capacity to Support Future Growth

    CANTON, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, announced plans to expand manufacturing capacity with a long-term lease for a 122,000-square foot state-of-the-art biomanufacturing facility located at 100 Technology Way in Smithfield, Rhode Island. "We are pleased to join the Rhode Island life sciences community as we expand our New England manufacturing capacity to support future growth," said Gary S. Gillheeney, Sr., President, Chief Executive Officer, a

    11/22/24 4:05:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock

    CANTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that it has entered into a Subscription Agreement with affiliates of Avista Healthcare Partners ("Investors") for the sale of its Series A Convertible Preferred Stock ("Preferred Stock") in a private placement for gross proceeds of $130 million to the Company, prior to deducting placement agent commissions, fees and other offering expenses. The Company intends to use the net proceeds from the

    11/12/24 4:01:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth

    Alan Fisher appointed Chair of the Board of DirectorsTim Cunningham joins as Chief Financial Officer ADELAIDE, Australia and CAMBRIDGE, Mass., July 03, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX, ASX: BNO))) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced key leadership updates to drive its ongoing transformation to a U.S.-focused company, streamline its allocation of capital, and support its next stage of strategic growth. Alan Fisher, currently a non-executive me

    7/3/23 6:00:00 AM ET
    $BNOX
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORGO
    Financials

    Live finance-specific insights

    View All

    Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance

    CANTON, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Results Summary: Net product revenue of $150.5 million for the third quarter of 2025, an increase of $35.3 million compared to net product revenue of $115.2 million for the third quarter of 2024. Net product revenue for the third quarter of 2025 consists of: Net product revenue from Advanced Wound Car

    11/6/25 4:05:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025

    CANTON, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that third quarter of fiscal year 2025 financial results will be reported after the market closes on Thursday, November 6th. Management will host a conference call at 5:00 p.m. Eastern Time on November 6th to discuss the results of the quarter, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access

    10/1/25 4:05:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Organogenesis Holdings Inc. Reports Second Quarter 2025 Financial Results

    CANTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Results Summary: Net product revenue of $100.8 million for the second quarter of 2025, a decrease of $29.5 million compared to net product revenue of $130.2 million for the second quarter of 2024. Net product revenue for the second quarter of 2025 consists of: Net product revenue from Advanced Wound

    8/7/25 4:05:00 PM ET
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care